Use of agents to treat eosinophil-associated pathologies
US6071910A · kind A · utility
21Cited by
7References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 1997 |
| Grant date | Jun 6, 2000 |
| Priority date | — |
| Expiry date | Dec 5, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/962
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.